VERAXA Biotech Advances VXA-222 Cancer Program and Expands Patent Portfolio

VERAXA Biotech (NASDAQ: VRXA), a company focused on designing novel cancer therapies, has announced a significant milestone in its oncology pipeline. The company's VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase, marking a key step forward in its development. This progress follows the successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With this phase complete, VERAXA will now focus on engineering the final bispecific ADC candidate by combining the antibody binders identified through the collaboration with its proprietary linker and conjugation technologies.

The advancement of VXA-222 is particularly notable because it leverages VERAXA's expertise in antibody engineering, even though it is not based on the company's BiTAC platform. This program is one of VERAXA's more advanced development efforts, and its progression underscores the company's ability to integrate various technologies to create promising therapeutic candidates. The company's pipeline is diversified, encompassing bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats, all aimed at treating difficult-to-tackle cancers.

In tandem with the VXA-222 progress, VERAXA has expanded its intellectual property portfolio, filing its first BiTAC-related patent applications and additional patents covering conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047. This robust IP strategy is critical for safeguarding the company's innovations and maintaining a competitive edge in the rapidly evolving field of cancer immunotherapy.

The implications of these developments are substantial. For VERAXA, advancing VXA-222 brings it closer to potential clinical trials, which could validate the efficacy of its bsADC approach. The expansion of the patent portfolio not only protects the company's current assets but also secures its future pipeline, deterring competitors and potentially opening avenues for licensing or partnerships. For the broader oncology community, the progress of VXA-222 adds to the growing body of evidence supporting bispecific ADCs as a promising class of therapeutics, capable of targeting cancer cells with greater precision and reducing off-target effects.

Investors and industry observers will be watching closely as VERAXA moves VXA-222 through preclinical validation. The successful combination of OmniAb's binders with VERAXA's technologies could yield a best-in-class candidate, positioning the company favorably in the competitive landscape. Moreover, the strengthened IP portfolio signals long-term viability and could enhance the company's attractiveness to potential collaborators or acquirers.

As VERAXA continues to build its pipeline and protect its innovations, the company remains focused on its mission to design novel therapies that address unmet medical needs in oncology. The recent milestones are a testament to the company's strategic execution and its commitment to advancing the next generation of antibody-based cancer treatments.